Differences in clinical characteristics and cardiovascular disease risk prediction among Chinese women with polycystic ovary syndrome phenotypes: a cross-sectional study - Scorecard - MDSpire
Advertisement
Differences in clinical characteristics and cardiovascular disease risk prediction among Chinese women with polycystic ovary syndrome phenotypes: a cross-sectional study
Clinical Scorecard: Clinical Profiles and Cardiovascular Risk Assessment in Chinese Women with Different Phenotypes of Polycystic Ovary Syndrome: A Cross-Sectional Analysis
At a Glance
Category
Detail
Condition
Polycystic Ovary Syndrome (PCOS) and associated cardiovascular disease (CVD) risk
Key Mechanisms
Phenotypic variations in PCOS influence metabolic abnormalities including BMI, insulin resistance (HOMA-IR), uric acid (UA), and lipid profiles, which mediate increased CVD risk
Target Population
Chinese women aged 20–50 years diagnosed with PCOS according to Rotterdam criteria
Care Setting
Endocrinology outpatient and clinical research settings
Key Highlights
PCOS phenotypes A (OA + HA + PCOM), B (OA + HA), and C (HA + PCOM) exhibit significantly higher BMI, waist circumference, blood pressure, uric acid, LDL-C, triglycerides, and insulin resistance compared to phenotype D (OA + PCOM).
Lifetime cardiovascular risk scores estimated by the China-PAR model are significantly elevated in phenotypes A, B, and C compared to phenotype D.
BMI, HOMA-IR, and uric acid significantly mediate the relationship between PCOS phenotypes and increased CVD risk, with BMI showing the largest mediating effect.
Guideline-Based Recommendations
Diagnosis
Diagnose PCOS using Rotterdam criteria requiring at least two of: hyperandrogenism (clinical or biochemical), oligo/anovulation, and polycystic ovarian morphology on ultrasound.
Classify PCOS into phenotypes A, B, C, and D based on combinations of these criteria.
Management
Implement individualized treatment strategies focusing on weight management and metabolic control, especially in phenotypes A, B, and C.
Consider lifestyle interventions targeting diet and physical activity to reduce BMI and insulin resistance.
Monitoring & Follow-up
Conduct regular cardiovascular risk assessments using validated models such as China-PAR in women with PCOS, particularly those with phenotypes A, B, and C.
Monitor metabolic parameters including BMI, insulin resistance indices (HOMA-IR), lipid profiles, and uric acid levels.
Risks
Recognize that phenotypes A, B, and C have significantly higher odds of elevated lifetime CVD risk compared to phenotype D.
Be aware that obesity and insulin resistance are major mediators increasing CVD risk in PCOS phenotypes.
Patient & Prescribing Data
Chinese women with PCOS phenotypes A, B, C, and D aged 20–50 years
Phenotypes A, B, and C require focused interventions on weight and metabolic abnormalities to mitigate elevated cardiovascular risk; phenotype D shows comparatively lower CVD risk.
Clinical Best Practices
Use standardized ultrasound criteria and experienced operators to assess polycystic ovarian morphology for accurate phenotype classification.
Adjust cardiovascular risk assessments for confounders such as diet, physical activity, and medication use.
Prioritize BMI reduction as it has the largest mediating effect on CVD risk among PCOS phenotypes.
Incorporate comprehensive metabolic profiling including insulin resistance and uric acid measurements in routine evaluation.
